🇺🇸 FDA

Intelligence · Clinical Pipeline

Autoimmune & immunology R&D Pipeline

Autoimmune, rheumatology, and immunology biologics in clinical development.

Programs
987

Quick answer

Autoimmune & immunology: NovaPharmaNews indexes 987 autoimmune & immunology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Autoimmune, rheumatology, and immunology biologics in clinical development.

Top sponsors

Page 8 of 21

  1. Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  2. Zilucoplan sodium

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  3. bimekizumab

    Lacuna Pharma Pty Ltd

    Axial Spondyloarthritis

    phase 3 small molecule active

    1 trial

  4. bimekizumab

    Lacuna Pharma Pty Ltd

    Active juvenile idiopathic arthritis subtypes enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  5. bimekizumab

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  6. bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).

    Lacuna Pharma Pty Ltd

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  7. blisibimod

    Santhera Pharmaceuticals (Deutschland) GmbH

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  8. bupivacaine liposome injectable suspension

    Pacira Ireland Limited

    Knee Osteoarthritis

    phase 3 small molecule completed

    1 trial

  9. dehydroepiandrosterone

    Ultragenyx UK Limited

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    3 trials

  10. deucravacitinib, Placebo to match BMS 986165 tablet

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate-to-Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  11. deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  12. deucravacitinib, Placebo to match deucravacitinib tablet

    Bristol-Myers Squibb Australia Pty Ltd

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  13. deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib

    Bristol-Myers Squibb Australia Pty Ltd

    Juvenile Psoriatic Arthritis (JPsA)

    phase 3 small molecule active

    1 trial

  14. hydroxychloroquine (Z0188)

    Sanofi Pasteur

    Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  15. ianalumab

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  16. ianalumab s.c. q4w

    Novartis Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule active

    1 trial

  17. mesalazine (Asacol®)

    Cardiff Oncology

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  18. mycophenolate mofetil (CellCept)

    Hoffmann-La Roche

    Myasthenia Gravis, Generalized

    phase 3 small molecule completed

    1 trial

  19. piclidenoson

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  20. placebo for risankizumab

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  21. placebo for risankizumab IV

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  22. risankizumab

    AbbVie

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  23. risankizumab IV

    AbbVie

    Ulcerative Colitis (UC)

    phase 3 small molecule completed

    1 trial

  24. risankizumab placebo, Risankizumab, ABBV-066 / Risankizumab, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  25. sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Rheumatoid Arthritis

    phase 3 small molecule completed

    6 trials

  26. secukinumab

    Novartis Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule terminated

    1 trial

  27. tacrolimus capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lupus Nephritis

    phase 3 small molecule terminated

    1 trial

  28. tocilizumab [RoActemra/Actemra]

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 3 small molecule completed

    3 trials

  29. total knee arthroplasty

    Hospital Authority, Hong Kong

    Osteoarthritis, Knee

    phase 3 mab active

    1 trial

  30. tulisokibart, Placebo to Subcutaneous or intravenous MK-7240 (Tulisokibart), tulisokibart

    Merck Sharp and Dohme

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  31. tulisokibart, tulisokibart, Placebo to MK-7240

    Merck Sharp and Dohme

    Ulcerative colitis

    phase 3 small molecule active

    1 trial

  32. voclosporin

    Aurinia Pharmaceuticals

    Psoriasis

    phase 3 small molecule completed

    3 trials

  33. -, MERCAPTOPURINE , -, Film-Coated Tablet without JNJ-77242113, JNJ-77242113, AZATHIOPRINE , METHOTREXATE , JNJ-77242113

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  34. -aminosalicylic acid

    Ultragenyx UK Limited

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  35. 608

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Axial Spondyloarthritis

    phase 2 small molecule active

    1 trial

  36. 626

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  37. 627

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  38. 68Ga-FAPI-46, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis, axial spondyloarthritis

    phase 2 small molecule active

    1 trial

  39. 75mg SHP647 (PF-00547659)

    Takeda

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  40. 80 mg DR-6MP

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  41. A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 other active

    1 trial

  42. A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  43. A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  44. A-623

    Santhera Pharmaceuticals (Deutschland) GmbH

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  45. ABBV-066, Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  46. ABBV-066, Lutikizumab, ABBV-382, ABBV-066 / Risankizumab, ABBV-8736

    AbbVie Deutschland GmbH & Co. KG

    Moderate to Severe Crohn’s Disease

    phase 2 small molecule active

    1 trial

  47. ABBV-154

    AbbVie

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  48. ACP-044 Dose A

    Acadia Pharmaceuticals B.V.

    Osteoarthritis Pain

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many autoimmune & immunology pipeline programs are tracked?

987 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.